항우울제와 한약제제의 병용투여지침 개발-에스시탈로프람과 보험 4종 한약제제를 중심으로
A Study on the Development of Guideline for Co-Administration of Four Types of Herbal Medicine and Escitalopram
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objectives: To develop guidelines for concomitant use of four herbal medicines (Gamisoyosan, Banhasasimtang, Ojeoksan, and Bojungikgitang) with escitalopram. Methods: A guideline development team was assembled and relevant prior research was systematically reviewed to gather evidence. The potential for drug interactions was evaluated by analyzing changes in pharmacokinetic parameters. Safety was assessed through the analysis of adverse drug reactions associated with combined use. Recommendations and concomitant administration guidelines were formulated through a consensus process. Results: No significant drug interactions were identified between the four herbal medicines and escitalopram, indicating no need for dosage adjustment of escitalopram. However, it is recommended to monitor potential adverse reactions during concurrent use. Conclusions: This study provides recommendations for combined use of four herbal medicines covered by domestic insurance combined with escitalopram. Further research on interactions between antidepressants and herbal medicine is necessary to refine and enhance concomitant administration guidelines.
Abstract
Objectives: To develop guidelines for concomitant use of four herbal medicines (Gamisoyosan, Banhasasimtang, Ojeoksan, and Bojungikgitang) with escitalopram. Methods: A guideline development team was assembled and relevant prior research was systematically reviewed to gather evidence. The potential for drug interactions was evaluated by analyzing changes in pharmacokinetic parameters. Safety was assessed through the analysis of adverse drug reactions associated with combined use. Recommendations and concomitant administration guidelines were formulated through a consensus process. Results: No significant drug interactions were identified between the four herbal medicines and escitalopram, indicating no need for dosage adjustment of escitalopram. However, it is recommended to monitor potential adverse reactions during concurrent use. Conclusions: This study provides recommendations for combined use of four herbal medicines covered by domestic insurance combined with escitalopram. Further research on interactions between antidepressants and herbal medicine is necessary to refine and enhance concomitant administration guidelines.
참고문헌 (24)
- Bains N, "Major Depressive Disorder" (2023), StatPearls
- Mathers CD, "Projections of global mortality and burden of disease from 2002 to 2030", PLoS Med, 3(11), pp.e442~ (2006)[DOI]
- Marvel CL, "Cognitive and neurological im-pairment in mood disorders", Psychiatr Clin North Am, 27(1), pp.19~36 (2004)[DOI]
- Knight MJ, "Cognitive dysfunction in major depressive disorder", Curr Opin Psychiatry, 31, pp.26~31 (2018)[DOI]
- Choi MK, "Symptoms of depression in Koreans and Japanese : A cross-cultural study", Mental Health Research, 15, pp.104~114 (1996)
- Clinical practive guideline of Korean Medicine, Depression, "The Society of Korean Medicine Neuropsychiatry", National Institute for Korean Medicine Development, 35~, pp.11-B554036-000055-01 (2024)
- The Textbook Compilation Committee of Neuropsychiatry of Korean Medical Schools in Nation, "The Neuropsychiatry of Oriental medicine", pp.249~476 (2016), Jipmoon-Dang
- Clinical Practive Guideline of Korean Medicine, Depression, "The Society of Korean Medicine Neuropsychiatry", National Institute for Korean Medicine Development, 162~174, pp.11-B554036-000055-01 (2024)
- Edinoff AN, "Selective serotonin reuptake inhibitors and adverse effects : a narrative review", Neurol Int, 13(3), pp.387~401 (2021)[DOI]
- "Drug Safety"[URL]
- Kim ST, "HIRA big data Brief Volume 2, Issue 1", Insurance Review & Assessment Service, 41~48 (2018)
- von Moltke LL, "Escitalopram(S-citalopram)and its metabolites in vitro : cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram", Drug Metab Dispos, 29(8), pp.1102~1109 (2001)
- Noehr-Jensen L, "Escitalopram is a weak inhibitor of the CYP2D6-catalyzed O-demethylation of(+)-tramadol but does not reduce the hypoalgesic effect in experimental pain", Clin Pharmacol Ther, 86, pp.626~633 (2009)[DOI]
- Noehr-Jensen L, "Impact of CYP2C19 phenotypes on escitalopram metabolism and an evaluation of pupillometry as a serotonergic biomarker", Eur J Clin Pharmacol, 65(9), pp.887~894 (2009)[DOI]
- "Lexapro Tab. 5 mg drug information" (2000)[URL]
- Jung YS, "Assessment of Pharmacokinetic Effects of Herbal Medicines on Escitalopram", Ther Clin Risk Manag, 20, pp.151~160 (2024)[DOI]
- The Development Guidance of Co-administration Guideline for Herbal Medicine and Chemical Drug, "Cho SY", National Institute for Korean Medicine Development, ~, pp.11-B554036-000055-01 (2022)
- Clinical drug interaction studies-cytochrome P450 enzyme-and transporter-mediated drug interactions guidance for industry, "Food and Drug Administration clinical pharmacology", FDA, 1~27 (2020)
- Son YW, "Drug interaction research and labeling guidelines", Ministry of Food and Drug Safety, 1~37 (2015)
- "Approval review of Lexapro: Medical review"[URL]
- "Hanpoong Gamisoyosan Soft Extract drug information" (2000)[URL]
- Kim YH, "Efficacy of a Traditional Herbal Formula, Banha-Sasim-Tang in Functional Dyspepsia Classified as Excess Pattern", Front Pharmacol, 12, pp.698887~ (2021)[DOI]
- "Hanpoong Ojeoksan Soft Ext. drug information" (2000)[URL]
- "Hanpoong Bojungikgitang Soft Ext. drug information" (2000)[URL]